Palatin Technologies and King Pharmaceuticals Report Positive Data from Clinical Trial Evaluating Co-administration of PT-141 and Viagra
Palatin Technologies, Inc. and King Pharmaceuticals, Inc. announced today positive results from a clinical study evaluating the effect of co-administration of intranasal PT-141 and Generic Viagra in patients with erectile dysfunction (ED). The purpose of this study was to evaluate the potential additive effect of treating ED patients with both PT-141, which initiates erections via a central nervous system mechanism of action, and Viagra, a peripheral vasodilator indicated for erectile dysfunction. Viagra.
